

# C Blake Gilks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1384286/c-blake-gilks-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

357  
papers

26,864  
citations

88  
h-index

152  
g-index

376  
ext. papers

31,544  
ext. citations

6.9  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
357	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , <b>2022</b> , 41, 12-19	3.2	3
356	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. <i>Nature Communications</i> , <b>2022</b> , 13, 896	17.4	4
355	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.. <i>Gynecologic Oncology</i> , <b>2022</b> , 165, 376-384	4.9	2
354	HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva.. <i>Modern Pathology</i> , <b>2022</b> ,	9.8	1
353	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. <i>Journal of Pathology</i> , <b>2021</b> ,	9.4	3
352	Immunoreactive Acellular Keratin in Sentinel Lymph Nodes From a Patient With Endometrioid Carcinoma of the Endometrium With Squamous Differentiation: A Case Report of a Potential Diagnostic Pitfall. <i>International Journal of Gynecological Pathology</i> , <b>2021</b> , 40, 355-358	3.2	
351	Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 498-506	6.7	17
350	Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , <b>2021</b> , 40, 391-399	3.2	2
349	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. <i>International Journal of Gynecological Pathology</i> , <b>2021</b> , 40, 487-494	3.2	0
348	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , <b>2021</b> , 127, 2409-2422	6.4	14
347	Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 1038-1046	6.7	0
346	Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. <i>Histopathology</i> , <b>2021</b> , 79, 533-543	7.3	4
345	Primary mucinous ovarian neoplasms rarely show germ cell histogenesis. <i>Histopathology</i> , <b>2021</b> , 78, 640-643		2
344	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. <i>Modern Pathology</i> , <b>2021</b> , 34, 508-518	9.8	19
343	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , <b>2021</b> , 34, 194-206	9.8	6
342	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. <i>Mod Pathol</i> 2020; 33:871-879. <i>Modern Pathology</i> , <b>2021</b> , 34, 1031-1032	9.8	3
341	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 568-578	4.9	7

340	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. <i>Human Pathology</i> , <b>2021</b> , 108, 1-11	3.7	3
339	Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. <i>Histopathology</i> , <b>2021</b> , 78, 424-433	7.3	8
338	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 243-252	5.3	7
337	p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 907-913	3.5	8
336	Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. <i>Journal of Pathology</i> , <b>2021</b> , 253, 355-365	9.4	16
335	Online Training and Self-assessment in the Histopathologic Classification of Endocervical Adenocarcinoma and Diagnosis of Pattern of Invasion: Evaluation of Participant Performance. <i>International Journal of Gynecological Pathology</i> , <b>2021</b> , 40, S14-S23	3.2	1
334	Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , <b>2021</b> , 18, 3464-3474	5.6	1
333	Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 783-788	3.5	6
332	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. <i>Journal of Pathology: Clinical Research</i> , <b>2020</b> , 6, 252-262	5.3	16
331	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , <b>2020</b> , 101, 40-52	3.7	2
330	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4402-4413	12.9	8
329	Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. <i>Histopathology</i> , <b>2020</b> , 77, 92-99	7.3	16
328	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5411-5423	12.9	21
327	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 36-45	4.9	5
326	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 100-106	3.5	12
325	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 12-20	4.9	7
324	Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 3-11	4.9	29
323	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. <i>Modern Pathology</i> , <b>2020</b> , 33, 1595-1605	9.8	40

322	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. <i>Modern Pathology</i> , <b>2020</b> , 33, 1649-1659	9.8	10
321	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240412	3.7	1
320	Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. <i>Histopathology</i> , <b>2020</b> , 76, 521-530	7.3	2
319	Use of Immunohistochemical Markers (HNF-1 $\alpha$ , Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 344-353	3.2	5
318	Napsin-A and AMACR are Superior to HNF-1 $\alpha$ in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2020</b> , 28, 593-601	1.9	10
317	The most important discoveries of the past 50 years in gynaecological pathology. <i>Histopathology</i> , <b>2020</b> , 76, 6-10	7.3	3
316	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 552-560	4.9	21
315	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 537-545	3.2	8
314	Interpretation of somatic POLE mutations in endometrial carcinoma. <i>Journal of Pathology</i> , <b>2020</b> , 250, 323-335	9.4	70
313	Clinicopathological and molecular characterisation of multiple-classifier endometrial carcinomas. <i>Journal of Pathology</i> , <b>2020</b> , 250, 312-322	9.4	83
312	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , <b>2020</b> , 250, 336-345	9.4	56
311	Vulval squamous cell carcinoma and its precursors. <i>Histopathology</i> , <b>2020</b> , 76, 128-138	7.3	30
310	Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 19-25	3.2	2
309	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 97-104	4.9	19
308	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 495-502	6.7	10
307	Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 420-427	3.2	2
306	Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 514-521	3.2	
305	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. <i>Journal of Pathology</i> , <b>2020</b> , 252, 178-188	9.4	15

304	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin <b>2020</b> , 8,		7
303	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. <i>Cancer Medicine</i> , <b>2020</b> , 9, 6507-6514	4.8	2
302	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line <b>2020</b> , 15, e0240412		
301	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line <b>2020</b> , 15, e0240412		
300	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line <b>2020</b> , 15, e0240412		
299	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line <b>2020</b> , 15, e0240412		
298	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , <b>2019</b> , 10, 3935	17.4	59
297	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 441-448	4.9	39
296	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. <i>Human Pathology</i> , <b>2019</b> , 92, 39-47	3.7	2
295	Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 353-356	3.5	11
294	Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma. <i>Histopathology</i> , <b>2019</b> , 75, 442-445	7.3	6
293	Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 487-495	4.9	41
292	Synchronous carcinomas of endometrium and ovary: A pragmatic approach. <i>Gynecologic Oncology Reports</i> , <b>2019</b> , 27, 72-73	1.3	2
291	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , <b>2019</b> , 38, 353-362	3.2	25
290	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. <i>Histopathology</i> , <b>2019</b> , 75, 813-824	7.3	9
289	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. <i>International Journal of Gynecological Pathology</i> , <b>2019</b> , 38 Suppl 1, S40-S63	3.2	80
288	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 628-638	6.7	25
287	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2537-2548	12.9	50

286	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. <i>International Journal of Gynecological Pathology</i> , <b>2019</b> , 38, 119-127	3.2	6
285	Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. <i>International Journal of Gynecological Pathology</i> , <b>2019</b> , 38, 189-195	3.2	11
284	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. <i>International Journal of Gynecological Pathology</i> , <b>2019</b> , 38 Suppl 1, S123-S131	3.2	119
283	Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2019</b> , 27, 558-563	1.9	17
282	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 307-320	6.4	14
281	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , <b>2018</b> , 42, 561-568	6.7	117
280	DICER1 hot-spot mutations in ovarian gynandroblastoma. <i>Histopathology</i> , <b>2018</b> , 73, 306-313	7.3	9
279	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , <b>2018</b> , 31, 1107-1115	11.5	27
278	Case report: an identical twin with Sertoli-Leydig cell tumor. <i>Gynecological Endocrinology</i> , <b>2018</b> , 34, 563-566	5.6	2
277	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 885-896	5.1	24
276	Synchronous tumours of the female reproductive tract. <i>Pathology</i> , <b>2018</b> , 50, 214-221	1.6	15
275	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. <i>BMC Cancer</i> , <b>2018</b> , 18, 254	4.8	12
274	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , <b>2018</b> , 18, 347	4.8	42
273	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 450-459	7.8	8
272	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , <b>2018</b> , 37, 324-330	3.2	10
271	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 480-486	8.7	38
270	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , <b>2018</b> , 173, 1755-1769	9.2	159
269	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 53-60	4.9	30

268	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , <b>2018</b> , 31, 652-659	9.8	9
267	Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. <i>International Journal of Gynecological Cancer</i> , <b>2018</b> , 28, 1624-1630	3.5	3
266	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1401-1409	8.7	100
265	A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , <b>2018</b> , 42, 1596-1606	6.7	63
264	Does MMR status in endometrial cancer influence response to adjuvant therapy?. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 76-81	4.9	16
263	Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss. <i>Histopathology</i> , <b>2018</b> , 73, 703-705	7.3	5
262	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , <b>2017</b> , 123, 802-813	6.4	267
261	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4086-4094	12.9	83
260	Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. <i>Histopathology</i> , <b>2017</b> , 71, 238-246	7.3	56
259	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. <i>Histopathology</i> , <b>2017</b> , 71, 446-452	7.3	15
258	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , <b>2017</b> , 49, 856-865	36.3	141
257	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 555-561	3.2	25
256	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1835-1848	59.2	310
255	High-grade serous carcinoma of tubo-ovarian origin: recent developments. <i>Histopathology</i> , <b>2017</b> , 71, 339-356	7.3	48
254	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 245-252	6.7	56
253	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 230-239	3.2	25
252	Ovarian carcinoma histotype in Lynch syndrome. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 20, 140-141	1.3	1
251	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. <i>Histopathology</i> , <b>2017</b> , 70, 56-69	7.3	18

250	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , <b>2017</b> , 3, 279-293	5.3	44
249	Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention. <i>Clinical Obstetrics and Gynecology</i> , <b>2017</b> , 60, 686-696	1.7	2
248	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, e173290	13.4	152
247	Assessment of CK17 as a Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 273-280	3.2	17
246	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. <i>Journal of Pathology</i> , <b>2017</b> , 243, 26-36	9.4	50
245	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , <b>2017</b> , 71, 1014-1017	7.3	5
244	HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 507-516	3.2	28
243	Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 289-293	3.2	25
242	Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 161-170	6.7	46
241	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 126-136	5.1	19
240	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. <i>Histopathology</i> , <b>2017</b> , 70, 185-194	7.3	10
239	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. <i>Nature Reviews Cancer</i> , <b>2017</b> , 17, 65-74	31.3	168
238	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 172-179	3.2	27
237	A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , <b>2017</b> , 71, 736-742	7.3	19
236	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , <b>2016</b> , 68, 916-24	7.3	45
235	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , <b>2016</b> , 29, 1586-1593	9.8	59
234	Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 993-999	8.7	48
233	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , <b>2016</b> , 143, 46-53	4.9	94



232	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , <b>2016</b> , 45, 119-125	2.8	17
231	The cell surface mucin podocalyxin regulates collective breast tumor budding. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 11	8.3	19
230	Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2865-73	12.9	93
229	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 430-41	3.2	121
228	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 483-90	4.4	24
227	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 417-26	8.7	27
226	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 148-54	4.9	26
225	Rare cancers: a sea of opportunity. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e52-e61	21.7	60
224	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , <b>2016</b> , 29, 302-14	9.8	85
223	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108, djv428	9.7	81
222	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 166-180	6.7	42
221	p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 385-93	3.2	43
220	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 230-7	3.2	31
219	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , <b>2016</b> , 69, 727-738	7.3	40
218	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 209-21	3.2	24
217	Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours. <i>Histopathology</i> , <b>2016</b> , 69, 560-9	7.3	42
216	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors of Low Malignant Potential) Based on Clinical Outcome. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 1155-64	6.7	24
215	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. <i>Surgical Pathology Clinics</i> , <b>2016</b> , 9, 189-99	3.9	19

214	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , <b>2016</b> , 48, 758-67	36.3	209
213	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , <b>2016</b> , 135, 741-56	6.3	18
212	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 559-563	4.9	19
211	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	37
210	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 1619-1630	7.8	77
209	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , <b>2016</b> , 238, 389-400	9.4	122
208	Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. <i>Histopathology</i> , <b>2015</b> , 67, 331-7	7.3	35
207	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , <b>2015</b> , 28, 1101-22	9.8	107
206	Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 141-6	4.9	23
205	Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 268-74	4.9	35
204	Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2457-63	2.2	134
203	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5955-64	5.6	48
202	Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery. <i>Gynecologic Oncology Reports</i> , <b>2015</b> , 12, 72-4	1.3	7
201	The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors. <i>Neoplasia</i> , <b>2015</b> , 17, 650-60	6.4	43
200	Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1 $\alpha$ . <i>International Journal of Gynecological Pathology</i> , <b>2015</b> , 34, 323-33	3.2	38
199	FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 618-23	6.7	19
198	Vulvar Acanthosis With Altered Differentiation (VAAD): Report of a Case With Progression to Poorly Differentiated Carcinoma Over a 5-Yr Period. <i>International Journal of Gynecological Pathology</i> , <b>2015</b> , 34, 385-9	3.2	15
197	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination. <i>International Journal of Gynecological Pathology</i> , <b>2015</b> , 34, 517-27	3.2	10

196	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 1548-57	6.7	50
195	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , <b>2015</b> , 6, 37663-77	3.3	98
194	Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. <i>Obstetrics and Gynecology</i> , <b>2015</b> , 125, 338-345	4.9	76
193	Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 52-60	6.7	54
192	Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 357-64	6.7	88
191	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. <i>Journal of Pathology</i> , <b>2015</b> , 236, 201-9	9.4	92
190	The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. <i>Pathology</i> , <b>2015</b> , 47, 423-31	1.6	35
189	Loss of the Notch effector RBPJ promotes tumorigenesis. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 37-52	16.6	39
188	Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. <i>FEBS Letters</i> , <b>2015</b> , 589, 302-9	3.8	8
187	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 33705-19	3.3	24
186	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 210, 471.e1-11	6.4	178
185	Better therapeutic trials in ovarian cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju029	9.7	27
184	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , <b>2014</b> , 27, 1386-93	9.8	55
183	Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. <i>Histopathology</i> , <b>2014</b> , 64, 840-6	7.3	22
182	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , <b>2014</b> , 64, 1004-13	7.3	84
181	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. <i>Histopathology</i> , <b>2014</b> , 65, 149-54	7.3	52
180	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , <b>2014</b> , 27, 255-61	9.8	86
179	HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2014</b> , 138, 1495-502	5	23

178	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. <i>Genome Research</i> , <b>2014</b> , 24, 1881-93	9.7	218
177	Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. <i>American Journal of Clinical Pathology</i> , <b>2014</b> , 142, 629-33	1.9	9
176	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1 $\beta$ and oestrogen receptor. <i>Histopathology</i> , <b>2014</b> , 64, 585-96	7.3	59
175	Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. <i>Histopathology</i> , <b>2014</b> , 64, 626-32	7.3	15
174	Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. <i>International Journal of Gynecological Pathology</i> , <b>2014</b> , 33, 483-91	3.2	30
173	The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1173-81	6.7	87
172	Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. <i>International Journal of Gynecological Pathology</i> , <b>2014</b> , 33, 560-7	3.2	21
171	Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3967-73	2.2	13
170	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. <i>Modern Pathology</i> , <b>2014</b> , 27, 128-34	9.8	168
169	Absence of BRCA/FMR1 correlations in women with ovarian cancers. <i>PLoS ONE</i> , <b>2014</b> , 9, e102370	3.7	7
168	Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. <i>Expert Review of Obstetrics and Gynecology</i> , <b>2013</b> , 8, 67-82		9
167	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 853-62	21.7	248
166	Patterns of spread of clear cell ovarian cancer: Case report and case series. <i>Gynecologic Oncology Case Reports</i> , <b>2013</b> , 6, 25-7		8
165	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , <b>2013</b> , 62, 59-70	7.3	71
164	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. <i>Modern Pathology</i> , <b>2013</b> , 26, 860-7	9.8	58
163	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. <i>Cell Cycle</i> , <b>2013</b> , 12, 1433-49	4.7	62
162	Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. <i>International Journal of Gynecological Pathology</i> , <b>2013</b> , 32, 529-35	3.2	25
161	Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1450-5	6.7	30

160	Histotype-genotype correlation in 36 high-grade endometrial carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1421-32	6.7	92
159	Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. <i>American Journal of Clinical Pathology</i> , <b>2013</b> , 140, 55-60	1.9	1
158	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 1677-86	4	53
157	Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. <i>Advances in Anatomic Pathology</i> , <b>2013</b> , 20, 378-86	5.1	44
156	Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. <i>Obstetrics and Gynecology</i> , <b>2013</b> , 121, 14-24	4.9	111
155	Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 650-8	6.7	41
154	Luteinized thecomas (thecomatosis) associated with sclerosing peritonitis exhibit positive staining with sex cord markers steroidogenic factor-1 (SF-1) and FOXL2. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1458-9	6.7	10
153	Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 874-81	6.7	214
152	Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 514-21	6.7	58
151	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , <b>2012</b> , 118, 681-8	6.4	62
150	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 239-52	4.7	41
149	Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. <i>American Journal of Surgery</i> , <b>2012</b> , 203, 654-659	2.7	17
148	Use of mutation profiles to refine the classification of endometrial carcinomas. <i>Journal of Pathology</i> , <b>2012</b> , 228, 20-30	9.4	227
147	HMG2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , <b>2012</b> , 60, 547-53	7.3	22
146	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2012</b> , 25, 740-50	9.8	113
145	Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 499-506	3.2	49
144	Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 234-42	59.2	332
143	Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1656-62	2.2	95

142	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 929-34	11.5	208
141	It sounded like a good idea at the time. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2012</b> , 34, 1127-1130	8	8
140	New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. <i>Obstetrics and Gynecology</i> , <b>2012</b> , 120, 935-40	4.9	22
139	The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 641-53	6.7	205
138	Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 1503-8	6.7	10
137	Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 1562-70	6.7	147
136	The role of the fallopian tube in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2012</b> , 10, 296-306	0.6	66
135	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. <i>Nature</i> , <b>2011</b> , 475, 226-30	50.4	801
134	CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 2100-7	5.8	28
133	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , <b>2011</b> , 12, 852-61	21.7	883
132	Frequency of known gene rearrangements in endometrial stromal tumors. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1364-72	6.7	105
131	Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 366-71	3.2	32
130	FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 484-94	6.7	143
129	Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 36-44	6.7	105
128	Patterns of p53 immunoreactivity in endometrial carcinomas: All or nothing staining is of importance. <i>Histopathology</i> , <b>2011</b> , 59, 786-8	7.3	63
127	Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 328-33	4.9	55
126	Surgical staging of early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2011</b> , 122, 460-1; author reply 461-2	4.9	1
125	Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , <b>2011</b> , 223, 567-73	9.4	98

124	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , <b>2011</b> , 224, 328-33	9.4	174
123	High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum. <i>Surgical Pathology Clinics</i> , <b>2011</b> , 4, 375-96	3.9	2
122	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , <b>2011</b> , 24, 512-21	9.8	79
121	Letter to the editor regarding Øoh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression <i>Modern Pathology</i> , <b>2011</b> , 24, 1281-2; author reply 1282-3	9.8	6
120	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2538-48	12.9	182
119	The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. <i>American Journal of Clinical Pathology</i> , <b>2011</b> , 136, 67-73	1.9	3
118	Testing women with endometrial cancer to detect Lynch syndrome. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2247-52	2.2	88
117	Copy number aberrations in benign serous ovarian tumors: a case for reclassification?. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7273-82	12.9	18
116	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , <b>2011</b> , 24, 277-87	9.8	29
115	Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 783-91	12.9	64
114	Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. <i>International Journal of Molecular Sciences</i> , <b>2011</b> , 12, 1334-58	6.3	29
113	Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. <i>PLoS ONE</i> , <b>2011</b> , 6, e21121	3.7	63
112	Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2011</b> , 135, 874-81	5	8
111	Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. <i>Pathology</i> , <b>2010</b> , 42, 637-42	1.6	5
110	Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 740968	4.5	37
109	Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2852-60	12.9	52
108	Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 133, 354-65	1.9	57
107	Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 134, 835-45	1.9	116

106	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1532-43	59.2	1208
105	Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1503-13	5.8	14
104	Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1132-8	6.7	14
103	Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 984-93	6.7	119
102	HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. <i>Annals of Surgery</i> , <b>2010</b> , 251, 1107-16	7.8	42
101	Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. <i>International Journal of Gynecological Pathology</i> , <b>2010</b> , 29, 99-107	3.2	76
100	Differences in tumor type in low-stage versus high-stage ovarian carcinomas. <i>International Journal of Gynecological Pathology</i> , <b>2010</b> , 29, 203-11	3.2	260
99	High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. <i>International Journal of Gynecological Pathology</i> , <b>2010</b> , 29, 343-50	3.2	129
98	Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. <i>Gynecologic Oncology</i> , <b>2010</b> , 116, 50-6	4.9	105
97	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , <b>2010</b> , 222, 191-8	9.4	115
96	Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. <i>PLoS ONE</i> , <b>2009</b> , 4, e6412	3.7	285
95	MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. <i>PLoS ONE</i> , <b>2009</b> , 4, e7314	3.7	76
94	The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. <i>PLoS ONE</i> , <b>2009</b> , 4, e7988	3.7	71
93	Adult-type granulosa cell tumors and FOXL2 mutation. <i>Cancer Research</i> , <b>2009</b> , 69, 9160-2	10.1	49
92	Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 4843-50	10.1	37
91	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. <i>Modern Pathology</i> , <b>2009</b> , 22, 393-402	9.8	196
90	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , <b>2009</b> , 22, 469-75	9.8	102
89	A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. <i>Modern Pathology</i> , <b>2009</b> , 22, 1519-31	9.8	70



88	Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract. <i>Surgical Pathology Clinics</i> , <b>2009</b> , 2, 823-34	3.9	2
87	Ovarian carcinoma pathology and genetics: recent advances. <i>Human Pathology</i> , <b>2009</b> , 40, 1213-23	3.7	181
86	Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 2347-56	5.8	69
85	Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2719-29	59.2	551
84	A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 14-21	6.7	181
83	The fibromatosis signature defines a robust stromal response in breast carcinoma. <i>Laboratory Investigation</i> , <b>2008</b> , 88, 591-601	5.9	86
82	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. <i>Modern Pathology</i> , <b>2008</b> , 21, 1413-20	9.8	3
81	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , <b>2008</b> , 110, 256-64	4.9	54
80	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. <i>Gynecologic Oncology</i> , <b>2008</b> , 110, 408-17	4.9	98
79	The origin of ovarian carcinomas: a developmental view. <i>Gynecologic Oncology</i> , <b>2008</b> , 110, 452-4	4.9	59
78	SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 125-31	4.9	6
77	Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. <i>Pathology</i> , <b>2008</b> , 40, 611-6	1.6	27
76	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , <b>2008</b> , 39, 1239-51	3.7	207
75	Prognostic significance of macrophage infiltration in leiomyosarcomas. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1423-30	12.9	124
74	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5697-704	2.2	230
73	Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 1835-53	6.7	129
72	Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 955-64	6.7	68
71	Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. <i>PLoS ONE</i> , <b>2008</b> , 3, e3409	3.7	35

70	Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. <i>PLoS Medicine</i> , <b>2008</b> , 5, e232	11.6	575
69	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 107, 249-57	4.4	140
68	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 110, 417-26	4.4	82
67	Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2008</b> , 452, 589-98	5.1	17
66	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 481-9	5	101
65	Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. <i>Modern Pathology</i> , <b>2007</b> , 20, 84-9	9.8	63
64	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , <b>2007</b> , 20, 1156-65	9.8	56
63	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , <b>2007</b> , 5, 33	11.4	44
62	Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 719-29	3.1	91
61	HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. <i>Reproductive Sciences</i> , <b>2007</b> , 14, 605-14	3	24
60	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. <i>Gynecologic Oncology</i> , <b>2006</b> , 100, 264-70	4.9	72
59	Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4562-70	5.6	80
58	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5637-44	2.2	159
57	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 690-5	11.5	351
56	Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. <i>Cancer Research</i> , <b>2006</b> , 66, 4872-9	10.1	129
55	Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. <i>American Journal of Surgery</i> , <b>2006</b> , 191, 581-7	2.7	50
54	Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. <i>Differentiation</i> , <b>2006</b> , 74, 1-10	3.5	41
53	MDM2 protein expression is a negative prognostic marker in breast carcinoma. <i>Modern Pathology</i> , <b>2006</b> , 19, 69-74	9.8	55

52	Synchronous and Metachronous Endocervical and Ovarian Neoplasms: A Different Interpretation of HPV Data. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1687-1689	6.7	5
51	Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 295-304	6.7	85
50	Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2005</b> , 24, 147-52	3.2	53
49	Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. <i>International Journal of Gynecological Pathology</i> , <b>2005</b> , 24, 205-17	3.2	36
48	Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 281-94	6.7	110
47	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <i>Oncogene</i> , <b>2005</b> , 24, 7281-9	9.2	57
46	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. <i>Laboratory Investigation</i> , <b>2005</b> , 85, 1392-404	5.9	95
45	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 48-55	4.9	80
44	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 684-94	4.9	93
43	Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. <i>Gynecologic Oncology</i> , <b>2005</b> , 98, 299-303	4.9	15
42	Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. <i>Cancer</i> , <b>2005</b> , 103, 1770-7	6.4	98
41	Targeted transcriptional repression of Gfi1 by GFI1 and GFI1B in lymphoid cells. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 2508-19	20.1	67
40	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6143-51	12.9	175
39	Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. <i>Cancer Research</i> , <b>2004</b> , 64, 5068-73	10.1	124
38	Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. <i>Cancer Research</i> , <b>2004</b> , 64, 6874-82	10.1	64
37	Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7958-64	12.9	15
36	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. <i>Modern Pathology</i> , <b>2004</b> , 17, 690-5	9.8	104
35	Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 315-9	4.9	21

34	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5367-74	12.9	2156
33	Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. <i>International Journal of Gynecological Pathology</i> , <b>2004</b> , 23, 200-5	3.2	97
32	Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. <i>International Journal of Gynecological Pathology</i> , <b>2004</b> , 23, 265-72	3.2	47
31	Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. <i>Cancer Research</i> , <b>2004</b> , 64, 286-91	10.1	77
30	Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. <i>International Journal of Gynecological Pathology</i> , <b>2004</b> , 23, 129-37	3.2	100
29	Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. <i>International Journal of Gynecological Pathology</i> , <b>2003</b> , 22, 29-36	3.2	69
28	Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. <i>American Journal of Pathology</i> , <b>2003</b> , 163, 1449-56	5.8	123
27	Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. <i>American Journal of Pathology</i> , <b>2003</b> , 163, 2383-95	5.8	115
26	EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. <i>Cell</i> , <b>2003</b> , 115, 523-35	56.2	345
25	Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. <i>Modern Pathology</i> , <b>2002</b> , 15, 365-71	9.8	37
24	Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. <i>Modern Pathology</i> , <b>2002</b> , 15, 1374-80	9.8	135
23	Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. <i>American Journal of Clinical Pathology</i> , <b>2002</b> , 117, 723-8	1.9	145
22	Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1557-65	5.8	180
21	Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium. <i>Fertility and Sterility</i> , <b>2002</b> , 78, 195-6	4.8	9
20	Early stage uterine papillary serous carcinoma of the endometrium. <i>Cancer</i> , <b>2001</b> , 91, 752-757	6.4	64
19	Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 395-9	4.9	5
18	Amyloidosis of the Uterine Cervix Presenting as Postmenopausal Bleeding. <i>Obstetrics and Gynecology</i> , <b>2001</b> , 98, 966-968	4.9	6
17	Early stage uterine papillary serous carcinoma of the endometrium <b>2001</b> , 91, 752		11

16	Mitotic arrest of endometrial epithelium after paclitaxel therapy for breast cancer. <i>International Journal of Gynecological Pathology</i> , <b>2000</b> , 19, 395-7	3.2	14
15	Uterine adenomyomas excluding atypical polypoid adenomyomas and adenomyomas of endocervical type: a clinicopathologic study of 30 cases of an underemphasized lesion that may cause diagnostic problems with brief consideration of adenomyomas of other female genital tract. <i>International Journal of Gynecological Pathology</i> , <b>2000</b> , 19, 107-127	3.2	95
14	Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2000</b> , 22, 244-52	5.7	131
13	Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. <i>Genesis</i> , <b>1999</b> , 25, 40-8		34
12	Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1998</b> , 158, 1907-13	10.2	50
11	Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. <i>American Journal of Surgical Pathology</i> , <b>1998</b> , 22, 113-20	6.7	67
10	Detection of the EWS/WT1 gene fusion by reverse transcriptase-polymerase chain reaction in the diagnosis of intra-abdominal desmoplastic small round cell tumor. <i>American Journal of Surgical Pathology</i> , <b>1996</b> , 20, 406-12	6.7	66
9	Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. <i>American Journal of Surgical Pathology</i> , <b>1994</b> , 18, 364-75	6.7	114
8	Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. <i>Chest</i> , <b>1994</b> , 106, 1622-4	5.3	20
7	Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. <i>American Journal of Surgical Pathology</i> , <b>1991</b> , 15, 415-29	6.7	276
6	Trichoblastic fibroma. A clinicopathologic study of three cases. <i>American Journal of Dermatopathology</i> , <b>1989</b> , 11, 397-402	0.9	28
5	Biological effects of biliary shock wave lithotripsy in swine. <i>Investigative Radiology</i> , <b>1989</b> , 24, 366-70	10.1	5
4	Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. <i>American Journal of Surgical Pathology</i> , <b>1989</b> , 13, 717-29	6.7	230
3	Effects of cigarette smoke on tissue uptake and retention of iron oxide in the guinea pig. <i>The American Review of Respiratory Disease</i> , <b>1988</b> , 137, 1382-4		12
2	A novel lymphocyte activation antigen present on allospecific primed lymphocytes and defined by the monoclonal antibody VG01. <i>Transplantation</i> , <b>1988</b> , 45, 978-84	1.8	4
1	Aluminum-induced pulmonary fibrosis: do fibers play a role?. <i>The American Review of Respiratory Disease</i> , <b>1987</b> , 136, 176-9		39